



# Kyowa Kirin Cares offers streamlined support for your patients

We know how important comprehensive support will be throughout your patients' journey while taking NOURIANZ<sup>®</sup>. From access and reimbursement assistance to treatment support, Kyowa Kirin Cares is here to help along the way.



# Complete the enrollment form to help your patients get personalized support from a dedicated case manager

Fill out the Kyowa Kirin Cares enrollment form, enclosed in this brochure, with your patient's information and fax it to 833-447-4399.

Upon receiving the completed enrollment form, a Kyowa Kirin Cares case manager will begin the benefits investigation (BI) process for your patient and notify you of the results.

After the BI is complete, a Kyowa Kirin Cares case manager will help your patient navigate their reimbursement and access options based on their insurance coverage.

Kyowa Kirin Cares will coordinate to get your eligible patients their regular prescription of NOURIANZ<sup>®</sup> (istradefylline) through a designated specialty pharmacy.

## Co-pay card program




4

Eligible patients may be able to fill their prescription for as little as \$20 per month through the co-pay card program. Additional terms and conditions, including annual limits, apply. Please see enclosed terms and conditions for details.

### Assistance with access and reimbursement

A Kyowa Kirin Cares case manager can help your patients understand their access options regardless of their insurance coverage or status.



<sup>a</sup>Patients must be US residents with an active primary commercial plan; patients with federal or state government insurance such as Medicare, Medicaid, and Tricare are not eligible for co-pay assistance. Other terms and conditions may apply.

<sup>b</sup>Commercially insured patients do not need to participate in Kyowa Kirin Cares to be eligible for co-pay assistance.

<sup>c</sup>Patients must be US residents with no active medical or pharmacy benefit insurance and an annual gross income ≤400% of the federal poverty level, confirmed by electronic income verification response or documented proof of income.

ר Please see the Important Safety Information inside this

 $^{
m J}$  brochure and full Prescribing Information in the pocket.

# Complete the enrollment form to help your patients get personalized support from a dedicated case manager

Fill out the Kyowa Kirin Cares enrollment form, enclosed in this brochure, with your patient's information and fax it to 833-447-4399.

Upon receiving the completed enrollment form, a Kyowa Kirin Cares case manager will begin the benefits investigation (BI) process for your patient and notify you of the results.

After the BI is complete, a Kyowa Kirin Cares case manager will help your patient navigate their reimbursement and access options based on their insurance coverage.

Kyowa Kirin Cares will coordinate to get your eligible patients their regular prescription of NOURIANZ<sup>®</sup> (istradefylline) through a designated specialty pharmacy.

## Co-pay card program



4

Eligible patients may be able to fill their prescription for as little as \$20 per month through the co-pay card program. Additional terms and conditions, including annual limits, apply. Please see enclosed terms and conditions for details.

# Connect your patients to treatment support

Kyowa Kirin Cares helps provide your patients with personal phone support along their journey with NOURIANZ.

A dedicated case manager will be available to

- Answer general questions about NOURIANZ
- Provide external resources when applicable
- Help patients manage barriers to adherence
- Help navigate their financial options

The information provided by the case manager to your patients is for informational purposes only and does not constitute medical advice. It is not intended to replace a discussion between you and your patient. All decisions regarding patient care must be made by a patient's healthcare provider considering the unique characteristics of each patient.

To speak with a Kyowa Kirin Cares nurse, call 833-KK-CARES (833-552-2737) Monday through Friday, 8 ам to 8 рм (ET), or visit www.KyowaKirinCares.com to learn more.

### **Important Safety Information**

#### Indication

NOURIANZ<sup>®</sup> (istradefylline) is an adenosine receptor antagonist indicated as adjunctive treatment to levodopa/carbidopa in adult patients with Parkinson's disease (PD) experiencing "off" episodes.

#### **Important Safety Information**

#### **Warning and Precautions**

- **Dyskinesia:** NOURIANZ in combination with levodopa may cause dyskinesia or exacerbate pre-existing dyskinesia. In clinical trials, 1% of patients treated with either NOURIANZ 20 mg or 40 mg discontinued treatment because of dyskinesia, compared to 0% for placebo.
- Hallucinations / Psychotic Behavior: Because of the potential risk of exacerbating psychosis, patients with a major psychotic disorder should not be treated with NOURIANZ. Consider dosage reduction or discontinuation if a patient develops hallucinations or psychotic behaviors while taking NOURIANZ.
- Impulse Control / Compulsive Behaviors: Patients treated with NOURIANZ and one or more medication(s) for the treatment of Parkinson's disease (including levodopa) may experience intense urges to gamble, increased sexual urges, intense urges to spend money, binge or compulsive eating, and/or other intense urges, and the inability to control these urges. In clinical trials, 1 patient treated with NOURIANZ 40 mg was

reported to have impulse control disorder, compared to no patient on NOURIANZ 20 mg or placebo.

#### **Drug Interactions**

The maximum recommended dosage in patients taking strong CYP3A4 inhibitors is 20 mg once daily. Avoid use of NOURIANZ with strong CYP3A4 inducers.

#### **Specific Populations:**

**Pregnancy:** Based on animal data, may cause fetal harm.

**Hepatic impairment:** The maximum recommended dosage of NOURIANZ in patients with moderate hepatic impairment is 20 mg once daily. Avoid use in patients with severe hepatic impairment.

#### **Adverse Reactions:**

The most common adverse reactions with an incidence  $\geq$ 5% and occurring more frequently than with placebo were dyskinesia (15%, 17%, and 8%), dizziness (3%, 6%, and 4%), constipation (5%, 6%, and 3%), nausea (4%, 6%, and 5%), hallucination (2%, 6%, and 3%), and insomnia (1%, 6%, and 4%) for NOURIANZ 20 mg, 40 mg, and placebo, respectively.

You are encouraged to report suspected adverse reactions to Kyowa Kirin, Inc. at 1-844-768-3544 or FDA at 1-800-FDA-1088 or www.fda.gov/medwatch.

Please see full Prescribing Information in the pocket.

# Kyowa Kirin Cares: helping patients along the way

Kyowa Kirin Cares provides information and resources for you and your patients to support them along their journey with NOURIANZ<sup>®</sup> (istradefylline).

Please fill out the enclosed enrollment form to get your patients started with access and reimbursement assistance.

When you enroll in Kyowa Kirin Cares, your patients will be able to







Find out about potential reimbursement options

Commercially insured patients do not need to participate in Kyowa Kirin Cares to be eligible for co-pay assistance.

To speak with a Kyowa Kirin Cares case manager, call 833-KK-CARES (833-552-2737) Monday through Friday, 8 ам to 8 рм (ET), or visit www.KyowaKirinCares.com to learn more.

Please see the Important Safety Information inside this brochure and full Prescribing Information in the pocket.

# **Gyowa kirin**

NOURIANZ is a registered trademark of Kyowa Kirin Co., Ltd. © 2020 Kyowa Kirin, Inc. All rights reserved. PM-US-KKI-0038 June 2020

